The Local Production and Assistance (LPA) unit supports Member States in strengthening sustainable local production and technology transfer to improve access to quality-assured health products in a holistic and strategic manner in collaboration with governments, partners, and other stakeholders. Local production has been discussed in World Health Assemblies since the 1970s. The adoption of Resolution WHA61.21 for the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA-PHI) brought a renewed focus on local production and related technology transfer as a strategy to promote innovation, build capacity and improve access to quality-assured medical products.
Many countries, particularly Low-Middle Income Countries (LMICs), need guidance and support to strengthen coherent policies and a conducive business environment, as well as for local production to be quality assured and sustainable. Requested by Member States, the LPA Unit has been providing holistic and coordinated support to strengthen local production and technology transfer in collaboration with UN agencies and other partners under WHA61.21, WHA71(8), WHA72.8 and others. This includes guidance tools, situational analyses for sustainable quality local production, fostering partnerships to seek consensus and a global approach in strengthening local production, capacity building and specialized technical assistance to achieve quality assurance and sustainability, risk-based product selection, and facilitating technology transfer for prioritized products and technologies.
Low- and middle-income countries (LMICs) are becoming increasingly interested in developing the local production of quality-assured medical products. LMICs view local production as a strategy to improve access to quality medical products, achieve universal health coverage, strengthen health security, and reach the health-related targets and broader development goals of the SDGs.
Local production can play a significant role towards the reliable supply of quality-assured, affordable health products. The LPA unit supports Member States in strengthening sustainable local production with setting strategies and roadmaps, conducting situational analyses for sustainable quality local production, building capacity of manufacturers, regulators and other stakeholders, and forging strategic partnerships and collaborations. The harmonized collaboration among the different parties can impact on the access to quality health products.
Technology transfer is a broad concept encompassing education and training, direct investment, licensing, movement of people, supply of materials and equipment, and other elements. Technology transfer can build capacity for quality local production in a relatively short time and bring the supply of essential health products closer to the public health needs.
Manufacturers, particularly in Low- and middle-income countries (LMICs), may face challenges in access to technology to build capacity. Technology transfer is a complex process that needs a holistic and collaborative approach. The LPA unit supports countries to facilitate technology transfer for local production with a focus on priority health products or technologies which have high public health impact, in collaboration with other WHO programmes. The LPA unit conducts landscape analyses on technology transfer for the local production of medical products, and continuously explores mechanisms to increase technology transfer and new opportunities for collaboration to promote technology transfer in developing countries in line with country needs.
The World Local Production Forum: Enhancing access to medicines and other health technologies (WLPF) brings the global community – foremost government...
From the WHO standpoint, the single most important aspect of China’s current policy with respect to the pharmaceutical sector is its close linkage...
In the 1960s, Indian policy-makers identified distortions in the domestic pharmaceutical market, and in 1970 decided to eliminate pharmaceutical product...
On 25 April 2017, the World Health Organization (WHO) convened an informal interagency consultation to discuss local production of essential medicines...
Appropriate, affordable and good quality medical devices are indispensable in healthcare services. They serve for the prevention, diagnosis and treatment...
Blood products include not only blood components – whole blood, red blood cells, platelets and plasma manufactured from single donations and intended...
Intellectual property plays an important role both for the researching pharmaceutical industry, which relies heavily on intellectual property to protect...
Equity in access to health technologies constitutes one of the goals towards achieving universal health coverage.The Global Strategy and Plan of Action...
The major objective of this initiative is to conserve human plasma that is currently discarded in many parts of the world and to improve access to essential...
LPA provides support through strategic partnerships, situational analysis, strategy/roadmap setting, technology transfer facilitation, capacity building and specialized technical assistance. For further information about provision of specialized technical
assistance,
please contact: